Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study.

Scott MJ, Xiang H, Hart DP, Palmer B, Collins PW, Stephensen D, Sima CS, Hay CRM.

Haemophilia. 2019 Mar;25(2):205-212. doi: 10.1111/hae.13616. Epub 2018 Nov 8.

PMID:
30408835
2.

Long-term outcomes from prophylactic or episodic treatment of haemophilia A: A systematic review.

O'Hara J, Sima CS, Frimpter J, Paliargues F, Chu P, Presch I.

Haemophilia. 2018 Sep;24(5):e301-e311. doi: 10.1111/hae.13546. Epub 2018 Jul 13.

PMID:
30004613
3.

Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database.

Hanke CW, Mhatre SK, Oliveri D, Zivkovic M, Caro I, Bergström D, Dawson K, Sima CS.

J Drugs Dermatol. 2018 Feb 1;17(2):143-148.

PMID:
29462221
4.

Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.

Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, Chren MM, Arron ST.

J Am Acad Dermatol. 2017 Oct;77(4):713-718. doi: 10.1016/j.jaad.2017.03.038. Epub 2017 Aug 2.

PMID:
28780365
5.

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG.

Cancer. 2017 Nov 1;123(21):4114-4121. doi: 10.1002/cncr.30861. Epub 2017 Jun 29.

6.

Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy.

Yang HX, Woo KM, Sima CS, Bains MS, Adusumilli PS, Huang J, Finley DJ, Rizk NP, Rusch VW, Jones DR, Park BJ.

Ann Surg. 2017 Feb;265(2):431-437. doi: 10.1097/SLA.0000000000001708.

7.

KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2016 Dec;40(12):1579-1590.

8.

Attaining Proficiency in Robotic-Assisted Minimally Invasive Esophagectomy While Maximizing Safety During Procedure Development.

Sarkaria IS, Rizk NP, Grosser R, Goldman D, Finley DJ, Ghanie A, Sima CS, Bains MS, Adusumilli PS, Rusch VW, Jones DR.

Innovations (Phila). 2016 Jul-Aug;11(4):268-73. doi: 10.1097/IMI.0000000000000297.

9.

A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.

Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LG, Cullen GD, Haque S, Sima CS, Ni A, Antonescu CR, Katabi N, Pfister DG.

Ann Oncol. 2016 Oct;27(10):1902-8. doi: 10.1093/annonc/mdw287. Epub 2016 Aug 26.

10.

A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.

Pietanza MC, Litvak AM, Varghese AM, Krug LM, Fleisher M, Teitcher JB, Holodny AI, Sima CS, Woo KM, Ng KK, Won HH, Berger MF, Kris MG, Rudin CM.

Lung Cancer. 2016 Sep;99:23-30. doi: 10.1016/j.lungcan.2016.04.014. Epub 2016 Apr 26.

11.

Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer.

Lipitz-Snyderman A, Sima CS, Atoria CL, Elkin EB, Anderson C, Blinder V, Tsai CJ, Panageas KS, Bach PB.

JAMA Intern Med. 2016 Oct 1;176(10):1541-1548. doi: 10.1001/jamainternmed.2016.4426.

12.
13.

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

Drilon A, Bergagnini I, Delasos L, Sabari J, Woo KM, Plodkowski A, Wang L, Hellmann MD, Joubert P, Sima CS, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely GJ, Kris MG.

Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7.

14.

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC.

Clin Lung Cancer. 2016 Sep;17(5):e121-e129. doi: 10.1016/j.cllc.2016.01.003. Epub 2016 Jan 21.

15.

ReCAP: Detection of Potentially Avoidable Harm in Oncology From Patient Medical Records.

Lipitz-Snyderman A, Weingart SN, Anderson C, Epstein AS, Killen A, Classen D, Sima CS, Fortier E, Atoria CL, Pfister D, Lipitz-Snyderman A, Weingart SN, Anderson C, Epstein AS, Killen A, Classen D, Sima CS, Fortier E, Atoria CL, Pfister D.

J Oncol Pract. 2016 Feb;12(2):178-9; e224-30. doi: 10.1200/JOP.2015.006874.

16.
17.

Pretreatment Dysphagia in Esophageal Cancer Patients May Eliminate the Need for Staging by Endoscopic Ultrasonography.

Ripley RT, Sarkaria IS, Grosser R, Sima CS, Bains MS, Jones DR, Adusumilli PS, Huang J, Finley DJ, Rusch VW, Rizk NP.

Ann Thorac Surg. 2016 Jan;101(1):226-230. doi: 10.1016/j.athoracsur.2015.06.062. Epub 2015 Oct 23.

18.

Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ, Kris MG, Shouery M, Bennett A, Atkinson T, Pietanza MC.

Clin Trials. 2016 Jun;13(3):331-7. doi: 10.1177/1740774515615540. Epub 2015 Nov 4.

19.

A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

Li BT, Drilon A, Johnson ML, Hsu M, Sima CS, McGinn C, Sugita H, Kris MG, Azzoli CG.

Ann Oncol. 2016 Jan;27(1):154-9. doi: 10.1093/annonc/mdv498. Epub 2015 Oct 20.

20.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.

Yeh YC, Kadota K, Nitadori J, Sima CS, Rizk NP, Jones DR, Travis WD, Adusumilli PS.

Eur J Cardiothorac Surg. 2016 Jan;49(1):e9-e15. doi: 10.1093/ejcts/ezv316. Epub 2015 Sep 15.

21.

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.

Eng J, Woo KM, Sima CS, Plodkowski A, Hellmann MD, Chaft JE, Kris MG, Arcila ME, Ladanyi M, Drilon A.

J Thorac Oncol. 2015 Dec;10(12):1713-9. doi: 10.1097/JTO.0000000000000671.

22.

Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration.

Kadota K, Eguchi T, Villena-Vargas J, Woo KM, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Oncotarget. 2015 Sep 29;6(29):27505-18. doi: 10.18632/oncotarget.4752.

23.

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.

Kadota K, Nitadori JI, Ujiie H, Buitrago DH, Woo KM, Sima CS, Travis WD, Jones DR, Adusumilli PS.

J Thorac Oncol. 2015 Sep;10(9):1301-1310. doi: 10.1097/JTO.0000000000000617.

24.

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, Jones DR, Adusumilli PS.

J Clin Oncol. 2015 Sep 10;33(26):2877-84. doi: 10.1200/JCO.2015.60.9818. Epub 2015 Aug 10.

25.

The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Ujiie H, Kadota K, Nitadori JI, Aerts JG, Woo KM, Sima CS, Travis WD, Jones DR, Krug LM, Adusumilli PS.

Oncoimmunology. 2015 Mar 19;4(6):e1009285. eCollection 2015 Jun.

26.

Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma.

Kadota K, Buitrago D, Lee MC, Villena-Vargas J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Lung Cancer. 2015 Sep;89(3):329-36. doi: 10.1016/j.lungcan.2015.06.003. Epub 2015 Jun 15.

27.

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.

Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME, Yu HA.

Cancer. 2015 Sep 15;121(18):3212-3220. doi: 10.1002/cncr.29493. Epub 2015 Jun 10.

28.

Provider Differences in Use of Implanted Ports in Older Adults With Cancer.

Lipitz-Snyderman A, Elkin EB, Atoria CL, Sima CS, Epstein AS, Blinder V, Sepkowitz KA, Bach PB.

Med Care. 2015 Jul;53(7):646-52. doi: 10.1097/MLR.0000000000000368.

29.

The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.

Lee MC, Buitrago DH, Kadota K, Ujiie H, Woo K, Sima CS, Travis WD, Jones DR, Adusumilli PS.

Oncoimmunology. 2014 Dec 21;3(11):e967142. eCollection 2014 Nov.

30.

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

Paik PK, Shen R, Won H, Rekhtman N, Wang L, Sima CS, Arora A, Seshan V, Ladanyi M, Berger MF, Kris MG.

Cancer Discov. 2015 Jun;5(6):610-21. doi: 10.1158/2159-8290.CD-14-1129. Epub 2015 Apr 30.

31.

Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Kadota K, Yeh YC, Villena-Vargas J, Cherkassky L, Drill EN, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Chest. 2015 Sep;148(3):711-721. doi: 10.1378/chest.14-3005.

32.

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.

Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, Riely GJ, Kris MG.

Cancer. 2015 Jun 15;121(12):2078-82. doi: 10.1002/cncr.29313. Epub 2015 Mar 17.

33.

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas.

Kadota K, Nitadori J, Sima CS, Ujiie H, Rizk NP, Jones DR, Adusumilli PS, Travis WD.

J Thorac Oncol. 2015 May;10(5):806-14. doi: 10.1097/JTO.0000000000000486.

34.

Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Kadota K, Villena-Vargas J, Nitadori J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Ann Surg Oncol. 2015 Sep;22(9):3136-43. doi: 10.1245/s10434-015-4374-x. Epub 2015 Jan 22.

35.

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, Ladanyi M, Rudin CM, Kris MG, Riely GJ.

J Thorac Oncol. 2014 Nov;9(11):1669-74. doi: 10.1097/JTO.0000000000000344.

36.

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ.

J Thorac Oncol. 2015 Mar;10(3):431-7. doi: 10.1097/JTO.0000000000000432.

37.

Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Litvak AM, Woo K, Hayes S, Huang J, Rimner A, Sima CS, Moreira AL, Tsukazan M, Riely GJ.

J Thorac Oncol. 2014 Dec;9(12):1810-5. doi: 10.1097/JTO.0000000000000363.

38.

Thirty-day mortality underestimates the risk of early death after major resections for thoracic malignancies.

McMillan RR, Berger A, Sima CS, Lou F, Dycoco J, Rusch V, Rizk NP, Jones DR, Huang J.

Ann Thorac Surg. 2014 Nov;98(5):1769-74; discussion 1774-5. doi: 10.1016/j.athoracsur.2014.06.024. Epub 2014 Sep 8.

39.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Riely GJ, Kris MG, Krug LM, Pietanza MC.

Lung Cancer. 2014 Nov;86(2):237-40. doi: 10.1016/j.lungcan.2014.08.007. Epub 2014 Aug 17.

40.

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

Drilon A, Sugita H, Sima CS, Zauderer M, Rudin CM, Kris MG, Rusch VW, Azzoli CG.

J Thorac Oncol. 2014 Sep;9(9):1272-7. doi: 10.1097/JTO.0000000000000256.

41.

Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.

Lou F, Sima CS, Rusch VW, Jones DR, Huang J.

Ann Thorac Surg. 2014 Nov;98(5):1755-60; discussion 1760-1. doi: 10.1016/j.athoracsur.2014.05.070. Epub 2014 Aug 7.

42.

A prospective trial comparing pain and quality of life measures after anatomic lung resection using thoracoscopy or thoracotomy.

Rizk NP, Ghanie A, Hsu M, Bains MS, Downey RJ, Sarkaria IS, Finley DJ, Adusumilli PS, Huang J, Sima CS, Burkhalter JE, Park BJ, Rusch VW.

Ann Thorac Surg. 2014 Oct;98(4):1160-6. doi: 10.1016/j.athoracsur.2014.05.028. Epub 2014 Jul 31.

43.

Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Ripley RT, McMillan RR, Sima CS, Hasan SM, Ahmad U, Lou F, Jones DR, Rusch VW, Rizk NP, Huang J.

Ann Thorac Surg. 2014 Sep;98(3):968-74. doi: 10.1016/j.athoracsur.2014.04.098. Epub 2014 Jul 16.

44.

Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Kadota K, Yeh YC, D'Angelo SP, Moreira AL, Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Aug;38(8):1118-27. doi: 10.1097/PAS.0000000000000246.

45.

Long-term central venous catheter use and risk of infection in older adults with cancer.

Lipitz-Snyderman A, Sepkowitz KA, Elkin EB, Pinheiro LC, Sima CS, Son CH, Atoria CL, Bach PB.

J Clin Oncol. 2014 Aug 1;32(22):2351-6. doi: 10.1200/JCO.2013.53.3018. Epub 2014 Jun 30.

46.

Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.

Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW, Adusumilli PS, Travis WD.

J Thorac Oncol. 2014 Aug;9(8):1126-39. doi: 10.1097/JTO.0000000000000253.

47.

Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement.

Yeh YC, Nitadori J, Kadota K, Yoshizawa A, Rekhtman N, Moreira AL, Sima CS, Rusch VW, Adusumilli PS, Travis WD.

Histopathology. 2015 Jun;66(7):922-38. doi: 10.1111/his.12468. Epub 2015 Feb 5.

48.

Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy.

Wang H, Sima CS, Beasley MB, Illei P, Saqi A, Nonaka D, Geisinger KR, Huang J, Moreira AL.

Arch Pathol Lab Med. 2014 May;138(5):658-63. doi: 10.5858/arpa.2013-0028-OA.

PMID:
24786123
49.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM.

Lung Cancer. 2014 Jun;84(3):271-4. doi: 10.1016/j.lungcan.2014.03.006. Epub 2014 Mar 14.

50.

A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.

Ho AL, Lipson BL, Sherman EJ, Xiao H, Fury MG, Apollo A, Seetharamu N, Sima CS, Haque S, Lyo JK, Sales R, Cox L, Pfister DG.

Invest New Drugs. 2014 Jun;32(3):549-54. doi: 10.1007/s10637-014-0073-x. Epub 2014 Feb 25.

PMID:
24566705

Supplemental Content

Support Center